TY - JOUR
T1 - Flavonoids as multi-target compounds
T2 - A special emphasis on their potential as chemo-adjuvants in cancer therapy
AU - Namdeo, Ajay G.
AU - Boddu, Sai H.S.
AU - Amawi, Haneen
AU - Ashby, Charles R.
AU - Tukaramrao, Diwakar B.
AU - Trivedi, Piyush
AU - Babu, R. Jayachandra
AU - Tiwari, Amit K.
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Flavonoids are low molecular weight, polyphenolic phytochemicals, obtained from secondary metabolism of various plant compounds. They have a spectrum of pharmacological efficacies, including potential anti-cancer efficacy. Natural flavonoids are present in fruits, vegetables, grains, bark, roots, stems, flowers, tea and wine. Flavonoids can attenuate or inhibit the initiation, promotion and progression of cancer by modulating various enzymes and receptors in diverse pathways that involve cellular proliferation, differentiation, apoptosis, in-flammation, angiogenesis and metastasis. Furthermore, in vitro, flavonoids have been shown to reverse multidrug resistance when used as chemo-adjuvants. Flavonoids (both natural and synthetic analogues) interact with several oncogenic targets through dependent and independent mechanisms to mediate their anticancer efficacy in different types of cancer cells.
AB - Flavonoids are low molecular weight, polyphenolic phytochemicals, obtained from secondary metabolism of various plant compounds. They have a spectrum of pharmacological efficacies, including potential anti-cancer efficacy. Natural flavonoids are present in fruits, vegetables, grains, bark, roots, stems, flowers, tea and wine. Flavonoids can attenuate or inhibit the initiation, promotion and progression of cancer by modulating various enzymes and receptors in diverse pathways that involve cellular proliferation, differentiation, apoptosis, in-flammation, angiogenesis and metastasis. Furthermore, in vitro, flavonoids have been shown to reverse multidrug resistance when used as chemo-adjuvants. Flavonoids (both natural and synthetic analogues) interact with several oncogenic targets through dependent and independent mechanisms to mediate their anticancer efficacy in different types of cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=85085265076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085265076&partnerID=8YFLogxK
U2 - 10.2174/1381612826666200128095248
DO - 10.2174/1381612826666200128095248
M3 - Review article
C2 - 32003663
AN - SCOPUS:85085265076
SN - 1381-6128
VL - 26
SP - 1712
EP - 1728
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 15
ER -